Wei-lai Xu

发表

Isocitrate dehydrogenase 2 mutations correlate with leukemic transformation and are predicted by 2-hydroxyglutarate in myelodysplastic syndromes

Jie Jin, Chao Hu, Weilai Xu, 2018, Journal of Cancer Research and Clinical Oncology.

The relation of SF3B1 mutation and intracellular iron in myelodysplastic syndrome with less than 5% bone marrow blasts

Yingwan Luo, Yanling Ren, Xinping Zhou, 2018, Leukemia & lymphoma.

Clinical significance of cytogenetic and molecular genetic abnormalities in 634 Chinese patients with myelodysplastic syndromes

Jie Jin, P. Lin, Yingwan Luo, 2021, Cancer medicine.

Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher‐risk myelodysplastic syndromes: a prospective multicenter single‐arm trial

Jie Jin, Yue-min Kuang, Yanling Ren, 2020, Hematological oncology.

Clinical and biological characteristics of acute myeloid leukemia with 20–29% blasts: a retrospective single-center study

Jie Jin, P. Lin, Yingwan Luo, 2018, Leukemia & lymphoma.

Analysis of clinical and molecular features of MDS patients with complex karyotype in China.

Jie Jin, P. Lin, Yingwan Luo, 2019, Blood cells, molecules & diseases.

Central nervous system leukemia in a patient with concurrent nasopharyngeal carcinoma and acute myeloid leukaemia

Jie Jin, Wei-lai Xu, W. Mai, 2017, Medicine.

Impact of mutational variant allele frequency on prognosis in myelodysplastic syndromes.

Jie Jin, Yingwan Luo, Shuanghong Zhu, 2020, American journal of cancer research.

Decitabine combined with low dose idarubicin and cytarabine (D-IA) followed by allo-HSCT improves acute myeloid leukemia and higher-risk myelodysplastic syndrome patient outcomes: results from a retrospective study

Jie Jin, Xinping Zhou, C. Mei, 2021, Leukemia & lymphoma.

Outcome prediction by the transcript level of BCR-ABL at 3 months in patients with chronic myeloid leukemia treated with imatinib--a single institution historical experience.

Jie Jin, Fei-fei Chen, Wei-lai Xu, 2014, Leukemia research.

[Clinical and experimental study of 38 cases with trisomy 8].

Jie Jin, Wei-lai Xu, Zhi-mei Chen, 2003, Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics.

Tigecycline and homoharringtonine synergistically target myeloid leukemia cells by inhibiting mitochondrial translation through mTOR/4EBP1 pathway

Jian Huang, Haiyang Yang, Hua Zhang, 2020 .

Efficacy and safety of homoharringtonine plus cytarabine and aclarubicin for patients with myelodysplastic syndrome-RAEB.

W. Qian, Chunmei Yang, Wei-lai Xu, 2016, Oncology letters.

Telomere attrition, and chromosome instability via downregulation of TRF2 contributes to arsenic trioxide-induced apoptosis of human T-cell leukemia cell line molt-4 cells

Jie Jin, W. Qian, Wei-lai Xu, 2007, Cancer biology & therapy.

Mutation status and burden can improve prognostic prediction of patients with lower‐risk myelodysplastic syndromes

Jie Jin, Yingwan Luo, Shuanghong Zhu, 2019, Cancer science.

Prognostic effects of clinical parameters, genetic abnormalities, and subtypes in primary gastric diffuse large B-cell lymphoma: a cohort analysis of 146 patients

Wei-lai Xu, H. Tong, Xue Jiang, 2022, Leukemia & lymphoma.

Decitabine for myelodysplastic syndromes: dose comparison in a real world clinical setting

Jie Jin, Fangjing Shi, P. Lin, 2019, Leukemia & lymphoma.

Decitabine improves overall survival in myelodysplastic syndromes-RAEB patients aged ≥60 years and has lower toxicities: Comparison with low-dose chemotherapy.

Jie Jin, Yingwan Luo, Chao Hu, 2019, Blood cells, molecules & diseases.

Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone

Jie Jin, W. Qian, P. Lin, 2017, Journal of Cancer Research and Clinical Oncology.

Acquired Robertsonian translocation is not always suggestive of poor prognosis: a case of acquired Rob(13;14) in Philadelphia chromosome-negative cells of chronic myelogenous leukemia

Jie Jin, Yungui Wang, Wei-lai Xu, 2010, Leukemia & lymphoma.

Efficacy and safety of early switching to an outpatient therapy model using oral arsenic plus retinoic acid based-regimen in newly diagnosed acute promyelocytic leukemia.

Jie Jin, Wei-lai Xu, H. Tong, 2019, Leukemia research.

Arsenic trioxide induces not only apoptosis but also autophagic cell death in leukemia cell lines via up-regulation of Beclin-1.

Jie Jin, W. Qian, Wei-lai Xu, 2007, Leukemia research.

The high NRF2 expression confers chemotherapy resistance partly through up-regulated DUSP1 in myelodysplastic syndromes

Jie Jin, Xiaomei Yan, M. Azam, 2018, Haematologica.

Diagnosis and management of acquired thrombotic thrombocytopenic purpura in southeast China: a single center experience of 60 cases

Jian Huang, Jie Jin, W. Qian, 2016, Frontiers of Medicine.

Acute myocardial/cerebral infarction as first/relapse manifestation in one acute promyelocytic leukemia patient.

Chunmei Yang, Wei-lai Xu, W. Mai, 2015, International journal of clinical and experimental medicine.

Improved long‐term survival in all Sanz risk patients of newly diagnosed acute promyelocytic leukemia treated with a combination of retinoic acid and arsenic trioxide‐based front‐line therapy

Jie Jin, Yungui Wang, W. Qian, 2018, Hematological oncology.

Downregulation of hTERT: An Important As2O3 Induced Mechanism of Apoptosis in Myelodysplastic Syndrome

Jie Jin, Yungui Wang, W. Qian, 2014, PloS one.

FLT3 and NPM1 mutations in Chinese patients with acute myeloid leukemia and normal cytogenetics

Jie Jin, W. Qian, Wei-lai Xu, 2010, Journal of Zhejiang University SCIENCE B.

The clinical impact of IKZF1 mutation in acute myeloid leukemia

Min Yang, Jianmin Yang, G. Tang, 2023, Experimental Hematology & Oncology.

Real‐world data of chronic myelomonocytic leukemia: A chinese single‐center retrospective study

Jie Jin, P. Lin, Yingwan Luo, 2021, Cancer medicine.

15‐days duration of venetoclax combined with azacitidine in the treatment of relapsed/refractory high‐risk myelodysplastic syndromes: A retrospective single‐center study

Yingwan Luo, Haiyang Yang, Xinping Zhou, 2022, Hematological oncology.

Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia

Jian Huang, J. Jin, J Jin, 2006, Leukemia.

Efficacy and safety of homoharringtonine plus cytarabine and aclarubicin for patients with myelodysplastic syndrome-RAEB.

W. Qian, Chunmei Yang, Wei-lai Xu, 2016, Oncology letters.

Homoharringtonine in combination with cytarabine and aclarubicin as induction therapy improves remission and survival of patients with higher risk myelodysplastic syndromes.

Jie Jin, W. Qian, Wei-lai Xu, 2010, Chinese Medical Journal.

Isocitrate dehydrogenase 2 mutations correlate with leukemic transformation and are predicted by 2-hydroxyglutarate in myelodysplastic syndromes

Jie Jin, Z. Zhuang, P. Lin, 2018, Journal of Cancer Research and Clinical Oncology.

Lower-dose decitabine improves clinical response compared with best supportive care in lower-risk MDS patients: a prospective, multicenter phase 2 study

Xinping Zhou, C. Mei, Liya Ma, 2021, Journal of Cancer.